EXPLORATION OF SAFETY, TOLERABILITY AND CLINICAL EFFICACY OF SOLNATIDE IMP IN PATIENTS INFECTED WITH THE 2019 NEW CORONAVIRUS

Grant number: Solnatide

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $1,755,022.98
  • Funder

    European Commission
  • Principle Investigator

    Pending
  • Research Location

    Austria, Europe
  • Lead Research Institution

    Apeptico (Austria)
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus